يحاول ذهب - حر

MoA reports 95% fund utilisation by research councils in last 5-year

August 21, 2025

|

Chronicle Pharmabiz

THE three autonomous bodies conducting R&D activities under the Union Ministry of Ayush (MoA) have utilised more than 97% of the budget released during the last five years, while another one has utilised over 95% of the allocated fund during the period, according to the Ministry.

- Gireesh Babu

The research councils Central Council for Research in Ayurvedic Sciences (CCRAS), Central Council for Research in Unani Medicine (CCRUM), Central Council of Research in Homoeopathy (CCRH), and Central Council of Research in Siddha (CCRS) has been actively contributing to the integration of Ayush systems with the modern system of medicine through a range of research initiatives.

According to data from the Ministry, CCRAS has utilised 97.4% of the allocated Rs. 1,814.71 crore, at Rs. 1,767.35 crore, while CCRUM has utilised 97.1% of the allocated Rs. 901.94 crore at Rs. 875.61 crore, and CCRH utilised 98.75% of Rs. 720.78 crore allocated, at Rs. 711.8 crore during the last five years.

CCRS has utilised 95.3% of the allocated Rs. 228.09 crore, at Rs 217.37 crore during the period.

As part of initiatives to strengthen its research activities, the CCRAS has initiated the process of obtaining NABH, NABL, and BIS certifications for its research institutes, in order to enhance institutional quality and credibility.

These accreditations aim to align the institutes with nationally accepted standards in healthcare services, laboratory practices, and operational protocols. Simultaneously, CCRAS is implementing focused capacity-building initiatives to strengthen the skills and competencies of its scientific and administrative staff.

المزيد من القصص من Chronicle Pharmabiz

Chronicle Pharmabiz

Chronicle Pharmabiz

Home-grown CAR-T cell therapies gaining ground

INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.

time to read

4 mins

November 27, 2025

Chronicle Pharmabiz

NPPA extends price fixation on orthopaedic implants for 1 year

IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

FICCI envisages it's Smart AAMs to boost healthcare

In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

DoP asked to bring policy for affordable drug pricing

THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Ramaiah emphasises need for bone health and osteoporosis diagnosis

RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Nathealth calls for action in 2026-27 Union Budget

NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Hotspots & growth opportunities in biomanufacturing

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

time to read

3 mins

November 27, 2025

Chronicle Pharmabiz

Omega Hospitals acquires Cytecare Hospitals

Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Devices sector hails withdrawal of QCOs

THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

'There is urgent need for tech-focused regulatory approach for med devices'

THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.

time to read

2 mins

November 27, 2025

Listen

Translate

Share

-
+

Change font size